Although PSC27‐BLEO CM increased the viability of PC3 cells exposed to MIT at 0.1 ~ 1.0 μM, a range of dose that was designed to resemble the serum concentrations of this clinical agent in cancer patients, antibody‐mediated AREG depletion markedly compromised stroma‐conferred cancer resistance with a result close to the condition when AREG mAb was combined with cetuximab, as evidenced by the remarkable shift of both PCa and BCa cell survival curves (p < .01; Figure 3h; Figure S3l). The gene discussed is AREG; the disease is cancer.